Is UZEDY Approved for Every 4 Weeks?
No, UZEDY (risperidone extended-release injectable suspension) is FDA-approved for once-monthly (every 4 weeks) or once every 2 months (every 8 weeks) subcutaneous administration in adults with schizophrenia.[1] The 50 mg or 100 mg dose is given monthly, while the 200 mg dose is given every 2 months. Dosing every 4 weeks aligns directly with the monthly regimen.
How Is UZEDY Dosed in Practice?
Treatment starts with a single 50 mg or 100 mg subcutaneous injection (no loading dose needed). After that:
- Monthly: 50 mg or 100 mg every 4 weeks.
- Every 2 months: 200 mg (after at least one monthly dose).
Doses can be adjusted based on response, but must stay within approved strengths. It's given by a healthcare provider using pre-filled syringes.[1][2]
What Happens If Given More or Less Often?
Sticking to the schedule prevents under- or overdosing. Giving it more frequently than approved (e.g., every 3 weeks) risks risperidone accumulation and side effects like extrapyramidal symptoms or prolactin elevation. Less frequent dosing may lead to relapse. Clinical trials confirmed steady-state levels with 4-week or 8-week intervals.[1]
Who Makes UZEDY and When Did It Launch?
Teva Pharmaceuticals and MedinCell developed UZEDY, approved by the FDA in April 2023. It's the first long-acting risperidone using SteadyTeq technology for consistent release without oral supplementation.[2]
How Does UZEDY Compare to Other Risperidone Injectables?
Unlike monthly Risperdal Consta (intramuscular, requires oral overlap), UZEDY is subcutaneous, monthly from day one, with no loading dose or supplementation. Rykindo (another risperidone LAI) offers 2- or 4-week IM options but needs oral tapering.[3]
[1]: UZEDY Prescribing Information (FDA)
[2]: Teva UZEDY Product Page
[3]: Drugs.com - UZEDY vs. Competitors